Skip to main content
. 2021 Jun 14;8:693021. doi: 10.3389/fsurg.2021.693021

Table 1A.

Distributions of selected baseline variables and outcome variables (N = 210).

Mean ± SE if continuous (Geometric Mean */ SE for Variables with Skewed Distributions)
Baseline variable Percentage with characteristic if categorical
DOT
<2015 38.6% (81/210)
≥2015 61.4% (129/210)
Recipient Age (yr) 49.4 ± 1.1 (N = 210)
(Median = 51.8, Range: 4–80)
Recipient age (yr)
<18 3.3% (7/210)
≥18, <50 42.4% (89/210)
≥50 54.3% (114/210)
Recipient gender
Female 35.7% (75/210)
Male 64.3% (135/210)
Recipient race/ethnicity
Black (non-Hispanic) 19.0% (40/210)
Hispanic 36.2% (76/210)
White (non-Hispanic) 42.4% (89/210)
Other 2.4% (5/210)
Recipient BMI (kg/m2) 26.4 ± 0.4 (N = 208)
(Median = 26.2, Range: 13.9–42.4)
Recipient pretransplant diabetes mellitus
No 79.5% (167/210)
Yes 20.5% (43/210)
Retransplant
No 96.7% (203/210)
Yes 3.3% (7/210)
Donor type
Living related 53.8% (113/210)
Living unrelated 46.2% (97/210)
Kidney
Right 10.0% (21/210)
Left 90.0% (189/210)
Number of donor arteries
1 76.7% (161/210)
2 19.5% (41/210)
3 3.8% (8/210)
Number of donor veins
1 99.0% (208/210)
2 1.0% (2/210)
Vascular reconstruction
No 73.3% (154/210)
Yes 26.7% (56/210)
Double-J ureteral stent placed
No 91.4% (192/210)
Yes 8.6% (18/210)
CIT (h) 0.86 ± 0.03 (N = 209)
(Median = 0.75, Range: 0.17–3.33)
WIT (min) 30.40 */ 1.02 (N = 209)
(Median = 28, Range: 16–117)
EBL (ml) 36.2 */ 1.06 (N = 210)
(Median = 30.0, Range: 10–780)
Operative Time (h) 4.17 ± 0.08 (N = 210)
(Median = 4.0, Range: 1.0–8.4)
Length of Hospital Stay (days) 4.40 */ 1.03 (N = 210)
(Median = 4, Range: 2–67)
Developed DGF
No 100.0% (210/210)
Yes 0.0% (0/210)
Developed a post-operative (or surgical) complication within 30 days (12 months) post-transplanta
No 96.2% (202/210)
Yes 3.8% (8/210)
Developed a urologic complication within 12 months post-transplanta
No 98.6% (207/210)
Yes 1.4% (3/210)
eGFR at 3 mo post-tx (ml/min/1.73m2) 77.1 ± 1.7 (N = 205)
(Median = 73.0, Range: 32.5–206.7)
eGFR at 6 mo post-tx (ml/min/1.73m2) 76.1 ± 1.8 (N = 200)
(Median = 75.0, Range: 8.3–190.3)
eGFR at 12 mo post-tx (ml/min/1.73m2) 75.5 ± 1.7 (N = 198)
(Median = 73.2, Range: 15.6–174.8)
eGFR at 36 mo post-tx (ml/min/1.73m2) 71.3 ± 2.3 (N = 93)
(Median = 69.9, Range: 12.0–148.1)
eGFR at 60 mo post-tx (ml/min/1.73m2) 64.9 ± 3.4 (N = 56)
(Median = 68.3, Range: 6.2–113.8)
Graft failure (i.e., return to permanent dialysis or retransplanted) (as of the last follow-up date)b
No 97.1% (204/210)
Yes 2.9% (6/210)
Death with a functioning graft (as of the last follow-up date)b
No 95.7% (201/210)
Yes 4.3% (9/210)
Graft loss (death uncensored) (as of the last follow-up date)b
No 92.9% (195/210)
Yes 7.1% (15/210)
a

Among the eight patients who developed a post-operative (or surgical) complication during the first 30 days (12 months) post-transplant, the following complications were observed: acute respiratory distress syndrome (ARDS) (N = 1), wound infection (N = 1), wound infection/necrosis (N = 1), c. difficile colitis/sepsis (N = 1), diverticulitis (N = 1), bladder leak (N = 1), ureteral stricture (N = 1), and possible ureteral leak (N = 1).

b

The date of last follow-up for this study was March 20, 2020. Median follow-up among 195 patients who were alive with a functioning graft as of the last follow-up date was 26.2 (range: 12.0–128.4) months post-transplant. The six causes and times-to-graft failure (return to permanent dialysis) were as follows (listed chronologically by time to graft failure): acute AMR at 5.4 months, acute T-cell mediated rejection at 41.8 months, MPGN recurrence at 58.0 months, CAI at 67.7 months, CAI at 68.2 months, and acute AMR/non-adherence at 86.7 months post-transplant. The nine causes of death with a functioning graft and times-to-death were as follows: cardiovascular event in six patients (at 3.3, 5.2, 7.9, 12.9, 59.9, and 69.6 months post-transplant), and infection/sepsis in three patients (at 0.8, 12.2, and 17.4 months post-transplant).